Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > DID RBC JUST GIVE UP WITH THEIR WEEKLY SCRIPT TRACKER?
View:
Post by GenericAdvocate on Jan 26, 2017 1:06pm

DID RBC JUST GIVE UP WITH THEIR WEEKLY SCRIPT TRACKER?

RBC used to publish a weekly script tracker of cxrx's major drugs that was often posted here

RBC's weekly reports seemed to stop for the company on Dec 6 according to my sources
 
I guess it looks like they just gave up eh?
Comment by oilwatcher13 on Jan 26, 2017 1:21pm
RBC dropped coverage when CXR stopped giving guidance.... full stop...
Comment by GenericAdvocate on Jan 26, 2017 2:24pm
Do you know this for sure?  Where did yo see this?  They downgraded to underperform price target of $1.00 and that was December 6th and was after they stopped giving guidance and after they pulled the financial forecasts?  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities